CareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing Growth
CareDx, Inc.CDNA raised its 2026 revenue and profitability outlook following strong transplant testing demand, improved ...
Model output · Signal date 2026-10-30
Caredx, Inc. (CDNA) Stock Forecast Oct. 30, 2026
Analysis updated on Oct. 30, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
This forecast was produced 3 trading days ago and has not been refreshed since; read it as historical, not as a current view.
Rating · 90D
NO CURRENT FORECAST
Alpha
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
n/a
Not ranked
Rank correlation · 90D
49.0%
Spearman, 357 dates
Market Cap
$4.52B
mid-cap · #9 of 26 peers
Summary
Caredx, Inc. (CDNA) stock forecast summary
This forecast was produced 3 trading days ago and has not been refreshed since; read it as historical, not as a current view.
Caredx, Inc. is a mid-cap company with a market capitalization of $4.52B. It ranks number 9 by market capitalization among the 26 Services-Medical Laboratories issuers in our coverage with a current forecast. Its ROE of 27.5% is the highest of the 14 peers that report one.
For CDNA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 49.0%, measured on 357 forecast dates between 2022-08-12 and 2026-07-31 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 17.0%, measured on 400 forecast dates between 2022-08-12 and 2026-09-30. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.9%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-30 signals)
Price
CDNA price chart and AI forecast
Cross-section · 2026-10-30
How CDNA ranks among 4891 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-09-30
Caredx, Inc. (CDNA) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Medical Laboratories peers listed below that report each metric.
Valuation & Market
| Metric | CDNA | Rank |
|---|---|---|
| Market Cap | $4.52B | 9/26 |
| P/E Ratio | 43.93x | 2/6 |
| P/B Ratio | 9.67x | 5/21 |
| EPS | $1.99 | – |
| Book Value/Share | $9.04 | – |
| Revenue/Share | $9.61 | – |
Profitability & Margins
| Metric | CDNA | Rank |
|---|---|---|
| ROE | 27.5% | 1/14 |
| ROA | 20.1% | 1/18 |
| ROIC | 22.9% | 1/21 |
| Operating Margin | 23.2% | 2/21 |
| Net Margin | 25.9% | 2/16 |
| EBT Margin | 25.0% | 2/21 |
| Tax Rate | -3.5% | – |
Financial Health
| Metric | CDNA | Rank |
|---|---|---|
| Current Ratio | 2.31x | 15/23 |
| Quick Ratio | 2.25x | 8/10 |
| D/E Ratio | 0.37x | 12/21 |
| Financial Leverage | 1.37x | 12/21 |
| Working Capital | $182M | 14/23 |
Cash Flow
| Metric | CDNA | Rank |
|---|---|---|
| Operating Cash Flow | $69M | 8/24 |
| OCF Growth YoY | 62.2% | 3/8 |
Operational Efficiency
| Metric | CDNA | Rank |
|---|---|---|
| Asset Turnover | 0.78x | 6/18 |
| Receivables Turnover | 10.4x | 3/19 |
| Fixed Assets Turnover | 18.4x | 3/17 |
| Days Sales Outstanding | 35 days | 17/19 |
Income Statement
| Metric | CDNA | Rank |
|---|---|---|
| Total Revenue | $497M | 9/19 |
| Operating Income | $115M | 3/23 |
| Net Income | $129M | 3/18 |
| R&D Expense | $84M | 7/18 |
| SG&A Expense | $344M | 7/18 |
Dividend & Shareholder Information
| Metric | CDNA | Rank |
|---|---|---|
| Shares Outstanding | 52M | – |
| Net Income Growth | 111.7% | 2/5 |
| EPS Growth | 80.9% | 2/6 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $321M | 50.1% of assets |
| Cash & Short-term Investments | $250M | 39.0% of assets |
| Accounts Receivable | $48M | 7.4% of assets |
| Inventory | $9M | 1.4% of assets |
| Total Liabilities | $174M | 27.1% of assets |
| Short-term Debt | $128M | 20.0% of assets |
Quarterly Financial Reports
CDNA quarterly financials and insider trading
Industry Peers · Services-Medical Laboratories
Caredx, Inc. (CDNA) industry peers
Companies classified under the same SEC industry code as Caredx, Inc. (Services-Medical Laboratories): 27 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| CDNA Caredx, Inc. | $4.52B | |
| NTRA Natera, Inc. | $56.02B | |
| LH Labcorp Holdings Inc. | $28.74B | |
| DGX Quest Diagnostics Inc | $27.18B | |
| GH Guardant Health, Inc. | $23.48B | |
| CAI Caris Life Sciences, Inc. | $9.70B | |
| GRAL Grail, Inc. | $6.23B | |
| RDNT Radnet, Inc. | $5.78B | |
| BLLN Billiontoone, Inc. | $5.21B | |
| VCYT Veracyte, Inc. | $3.94B | |
| CELC Celcuity Inc. | $3.38B | |
| FTRE Fortrea Holdings Inc. | $2.02B | |
| PSNL Personalis, Inc. | $1.68B | |
| FRNM Freenome, Inc. | $1.23B | |
| LMRI Lumexa Imaging Holdings, Inc. | $1.08B | |
| CSTL Castle Biosciences Inc | $1.07B | |
| FLGT Fulgent Genetics, Inc. | $533M | |
| BDSX Biodesix Inc | $222M | |
| XGN Exagen Inc. | $203M | |
| BNR Burning Rock Biotech Ltd | $117M | |
| SERA Sera Prognostics, Inc. | $78M | |
| MDXH Mdxhealth Sa | $18M | |
| AMS American Shared Hospital Services | $8M | |
| ACON Aclarion, Inc. | $5M | |
| ADVB Advanced Biomed Inc. | $3M | |
| BGLC Bionexus Gene Lab Corp | $3M | |
| RNLXY Renalytix Plc | N/A |
Where CDNA sits on the market map
Industrial Applications and Services · Services-Medical Laboratories
News
Caredx, Inc. (CDNA) stock news
CareDx Announces Third KOAR Analysis Published in Transplantation
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the publication ...
CareDx Inc (CDNA) Q3 2025 Earnings Report Preview: What To Expect
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
FAQ
Caredx, Inc. (CDNA) stock forecast FAQ
What is the Caredx, Inc. (CDNA) stock forecast?
This forecast was produced 3 trading days ago and has not been refreshed since; read it as historical, not as a current view.
How accurate are Caredx, Inc. stock predictions?
For CDNA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 49.0%, measured on 357 forecast dates between 2022-08-12 and 2026-07-31 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 17.0%, measured on 400 forecast dates between 2022-08-12 and 2026-09-30. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Caredx, Inc. forecasts updated?
Caredx, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 30, 2026.
Which companies are Caredx, Inc.'s industry peers?
27 issuers in our coverage, CDNA included, share the SEC industry code Services-Medical Laboratories. The largest are: Natera, Inc. (NTRA), Labcorp Holdings Inc. (LH), Quest Diagnostics Inc (DGX), Guardant Health, Inc. (GH), Caris Life Sciences, Inc. (CAI), Grail, Inc. (GRAL).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.